IRulya Therapeutics

IRulya Therapeutics (formerly Quince Therapeutics) is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for serious, underserved pulmonary conditions. The company's lead program is LAM-001, a proprietary, once-daily dry powder inhaled formulation of rapamycin (sirolimus) designed to deliver the mTOR inhibitor directly to the lungs while minimizing systemic exposure. IRulya is currently advancing LAM-001 in Phase 2 clinical trials for bronchiolitis obliterans syndrome (BOS), pulmonary hypertension associated with interstitial lung disease (PH-ILD), and sarcoidosis-associated pulmonary hypertension (SAPH). Additionally, the company's pipeline includes AIT-101, a selective PIKfyve inhibitor for amyotrophic lateral sclerosis (ALS), and AIT-102, a transcription factor Sp1 inhibitor for oncology indications.